Biomanufacturing for clinically advanced cell therapies
The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell imm...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Science and Business Media LLC
2019
|
| Online Access: | https://hdl.handle.net/1721.1/121979 |
| _version_ | 1826189508318593024 |
|---|---|
| author | Aijaz, Ayesha Li, Matthew Smith, David Khong, Danika LeBlon, Courtney Olabisi, Ronke M. Libutti, Steven Tischfield, Jay Maus, Marcela V. Deans, Robert Barcia, Rita N. Anderson, Daniel Griffith Ritz, Jerome Preti, Robert Parekkadan, Biju Fenton, Owen Shea |
| author2 | Massachusetts Institute of Technology. Department of Chemical Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Chemical Engineering Aijaz, Ayesha Li, Matthew Smith, David Khong, Danika LeBlon, Courtney Olabisi, Ronke M. Libutti, Steven Tischfield, Jay Maus, Marcela V. Deans, Robert Barcia, Rita N. Anderson, Daniel Griffith Ritz, Jerome Preti, Robert Parekkadan, Biju Fenton, Owen Shea |
| author_sort | Aijaz, Ayesha |
| collection | MIT |
| description | The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use. |
| first_indexed | 2024-09-23T08:16:16Z |
| format | Article |
| id | mit-1721.1/121979 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T08:16:16Z |
| publishDate | 2019 |
| publisher | Springer Science and Business Media LLC |
| record_format | dspace |
| spelling | mit-1721.1/1219792022-09-23T12:01:31Z Biomanufacturing for clinically advanced cell therapies Aijaz, Ayesha Li, Matthew Smith, David Khong, Danika LeBlon, Courtney Olabisi, Ronke M. Libutti, Steven Tischfield, Jay Maus, Marcela V. Deans, Robert Barcia, Rita N. Anderson, Daniel Griffith Ritz, Jerome Preti, Robert Parekkadan, Biju Fenton, Owen Shea Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Institute for Medical Engineering & Science Harvard University--MIT Division of Health Sciences and Technology Koch Institute for Integrative Cancer Research at MIT The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use. 2019-08-09T19:59:11Z 2019-08-09T19:59:11Z 2018-06 2017-07 2019-08-09T14:00:45Z Article http://purl.org/eprint/type/JournalArticle 2157-846X https://hdl.handle.net/1721.1/121979 Aijaz, Ayesha et al. "Biomanufacturing for clinically advanced cell therapies." Nature Biomedical Engineering 2, 6 (June 2018): 362–376 © 2018 The Author(s) en http://dx.doi.org/10.1038/s41551-018-0246-6 Nature Biomedical Engineering Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Springer Science and Business Media LLC PMC |
| spellingShingle | Aijaz, Ayesha Li, Matthew Smith, David Khong, Danika LeBlon, Courtney Olabisi, Ronke M. Libutti, Steven Tischfield, Jay Maus, Marcela V. Deans, Robert Barcia, Rita N. Anderson, Daniel Griffith Ritz, Jerome Preti, Robert Parekkadan, Biju Fenton, Owen Shea Biomanufacturing for clinically advanced cell therapies |
| title | Biomanufacturing for clinically advanced cell therapies |
| title_full | Biomanufacturing for clinically advanced cell therapies |
| title_fullStr | Biomanufacturing for clinically advanced cell therapies |
| title_full_unstemmed | Biomanufacturing for clinically advanced cell therapies |
| title_short | Biomanufacturing for clinically advanced cell therapies |
| title_sort | biomanufacturing for clinically advanced cell therapies |
| url | https://hdl.handle.net/1721.1/121979 |
| work_keys_str_mv | AT aijazayesha biomanufacturingforclinicallyadvancedcelltherapies AT limatthew biomanufacturingforclinicallyadvancedcelltherapies AT smithdavid biomanufacturingforclinicallyadvancedcelltherapies AT khongdanika biomanufacturingforclinicallyadvancedcelltherapies AT lebloncourtney biomanufacturingforclinicallyadvancedcelltherapies AT olabisironkem biomanufacturingforclinicallyadvancedcelltherapies AT libuttisteven biomanufacturingforclinicallyadvancedcelltherapies AT tischfieldjay biomanufacturingforclinicallyadvancedcelltherapies AT mausmarcelav biomanufacturingforclinicallyadvancedcelltherapies AT deansrobert biomanufacturingforclinicallyadvancedcelltherapies AT barciaritan biomanufacturingforclinicallyadvancedcelltherapies AT andersondanielgriffith biomanufacturingforclinicallyadvancedcelltherapies AT ritzjerome biomanufacturingforclinicallyadvancedcelltherapies AT pretirobert biomanufacturingforclinicallyadvancedcelltherapies AT parekkadanbiju biomanufacturingforclinicallyadvancedcelltherapies AT fentonowenshea biomanufacturingforclinicallyadvancedcelltherapies |